CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Zai Lab Limited Receives Breakthrough Therapy Designation For Bemarituzumab

Life Sciences Review Life Sciences Review | Thursday, September 30, 2021
Tweet

Zai Lab has been granted therapy designation by the CDE to treat gastric and gastro esophageal cancers that overexpress fibroblast growth factor receptor 2. (FGFR2b)


FREMONT, CA: The National Medical Products Administration's Center for Drug Evaluation (CDE) has granted Zai Lab Limited Breakthrough Therapy Designation for investigational bemarituzumab (FPA144) as a first-line treatment for patients with FGFR2b overexpression and HER2-negative metastatic and locally advanced gastric and GEJ cancers in combination with modified FOLFOX6 (fluoropyrimidine, leucovorin, and oxaliplatin).


Results from the Phase 2 FIGHT trial, which compared bemarituzumab plus chemotherapy (modified FOLFOX6) to chemotherapy alone in patients with FGFR2b overexpression and HER2-negative frontline advanced gastric or GEJ cancer, back up the designation. In the FIGHT trial, all three efficacy endpoints — PFS, OS, and ORR — achieved pre-specified statistical significance in the bemarituzumab arm versus the placebo arm. Additional study revealed a link between benefit and the prevalence of FGFR2b overexpression tumor cells, confirming the relevance of the FGFR2b target and bemarituzumab's effectiveness against it.


“In granting Breakthrough Therapy Designation, we are pleased to see that the CDE recognizes the promise of bemarituzumab. 


In combination with chemotherapy, bemarituzumab demonstrated clinically meaningful outcomes in key endpoints for patients with advanced gastric or GEJ cancer as a frontline therapy,” said Alan Sandler, M.D., president and head of global development, oncology, at Zai Lab. “We look forward to working with regulatory authorities in China as we advance bemarituzumab into global, registrational studies.”


More than one million new instances of stomach cancer are identified every year, with China accounting for over half of all cases. Approximately 30% of patients with advanced gastric and GEJ malignancies have FGFR2b overexpression, and almost 80% of these individuals are HER2-negative.


The Breakthrough Therapy Designation review policy is intended to encourage the development of drugs with obvious clinical benefits that are designed for the prevention or treatment of severe life-threatening diseases or diseases that have a significant impact on quality of life for which no existing treatment exists or where sufficient evidence indicates that the novel drug has advantages over existing treatments. The CDE prioritizes drugs that have been granted Breakthrough Therapy Designation in communications and receiving instructions to expedite medication development.


Weekly Brief

loading
Top 10 Leading BioTech Solution Companies - 2021
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/zai-lab-limited-receives-breakthrough-therapy-designation-for-bemarituzumab-nwid-583.html